Title: Comprehensive Risk Factors for Alzheimer's Disease and Cognitive Function Before Middle Age in the U.S.

Authors: Allison E. Aiello, PhD, Jennifer Momkus, MPH, Rebecca C. Stebbins, PhD, Yuan S. Zhang, PhD, Chantel L. Martin, PhD, Y. Claire Yang, PhD, Lauren Gaydosh, PhD, Taylor Hargrove, PhD, Adina Zeki Al Hazzouri, PhD, and Kathleen Mullan Harris, PhD
Affiliations:
Robert N. Butler Columbia Aging Center, Columbia University, New York, NY, USA (Allison E. Aiello, PhD, Rebecca C. Stebbins, PhD, Yuan S. Zhang, PhD, Adina Zeki Al Hazzouri, PhD)
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA (Allison E. Aiello, PhD, Adina Zeki Al-Hazzouri, PhD)
Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (Jennifer Momkus, MPH, Y. Claire Yang, PhD, Taylor Hargrove, PhD, Chantel L. Martin, PhD, Kathleen Mullan Harris, PhD)
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (Jennifer Momkus, MPH, Chantel L. Martin, PhD)
Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA (Yuan S. Zhang, PhD)
Department of Sociology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (Y. Claire Yang, PhD, Taylor Hargrove, PhD, Kathleen Mullan Harris, PhD)

Abstract

Importance: Alzheimer's disease (AD) is a major health concern in the U.S., but most research has focused on older populations. Few studies investigate AD risk factors and cognitive function in young to early midlife adults.

Objective: To examine whether key AD risk factors are associated with cognition before midlife.

Design, Setting, Participants: Data from the National Longitudinal Study of Adolescent to Adult Health (Add Health) were analyzed. Participants were enrolled in 1994-95 (grades 7-12) and followed through 2018. We analyzed survey and biomarker data from Waves IV (median age 28) and V (median age 38) .

Exposures: Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) score, APOE ε4 status, Amyloid Tau and Neurodegeneration markers (ATN), including total Tau and Neurofilament light (NfL), high sensitivity C-reactive protein (hsCRP), Interleukin (IL)-1β, IL-6, IL-8, IL-10, and Tumor necrosis factor alpha (TNF-α).

Main Outcomes: Immediate word recall, delayed word recall, and digit span backwards.

Results: We analyzed data separately in Wave IV (ranging from N=4,507 to N=11,449) and Wave V (ranging from N=529 to N=1,121). Approximately half were female. The CAIDE score was associated with all cognition measures in Wave IV. For example, among adults aged 24-34, each 1-point increase in CAIDE was associated with a 0.03 SD lower backward digit span score (95% CI: -0.04, -0.02). No significant associations were found between APOE ε4 and cognition. Total Tau was associated with immediate word recall in Wave V (β=-0.14, 95% CI: -0.24, -0.04). Wave IV hsCRP and Wave V IL-6 and IL-8 were also associated with lower cognitive scores.

Conclusions: Key risk factors for AD, including cardiovascular, ATN, and immune markers, are linked to cognitive function as early as ages 24-44, highlighting the need for early prevention in the US.

Background

Alzheimer's disease (AD) poses a global health challenge.[1] While most research in the United States (US) has focused on older populations, where the risk of dementia is highest, there is a lack of studies investigating risk factors for AD and cognitive function in young to early midlife adults before the onset of disease. Identifying pathways to AD and cognitive impairment prior to old age is critical for slowing the expected growth of AD in coming decades.

The landscape of risk factors that are known to shape AD risk in older age encompass social, behavioral, clinical, and biological dimensions.[1] On the social and behavioral side, factors such as lower educational attainment, physical inactivity, and smoking are notable risk factors. Clinically, health conditions such as diabetes, obesity, hypertension, and high cholesterol have been identified as consistent contributors to AD risk. In recent years, researchers have sought to combine the social, behavioral, and clinical risk factors into comprehensive risk scores for AD.[2] The Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) score is among the most extensively researched risk algorithm and integrates social, behavioral and biological risks including education, sex, age, cholesterol levels, blood pressure, body mass index, and physical activity.[3]

On the biological side, genetic, neurological, immune, and inflammatory molecules have been implicated as biomarkers of AD risk.[4] The genetic profile of apolipoprotein E (APOE) is a well-known risk factor for AD in older populations.[5] Moreover, brain-specific molecules related to lesions and neuropathology, such as amyloid plaques and neurofibrillary tangles, have been investigated as predictors of AD in later life. The amyloid (A), tau (T), and neurodegeneration (N) (known as ATN) biomarkers are increasingly promising for predicting AD risk in older populations.[6] Two commonly measured biomarkers are total tau and neurofilament light chain

(NfL). Both measures have been shown to be predictive of later life AD risk in older populations.[7,8] Furthermore, both central and peripheral immune and inflammatory mechanisms are increasingly recognized as pivotal in the pathogenesis of AD. A recent comprehensive review identified relatively consistent positive associations between several inflammation-related cytokines and AD risk, with the two most-studied markers being interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).[4] While also widely studied, C-reactive protein was less consistently associated with AD risk in this review, with approximately 25% of the studies demonstrating positive associations, 25% showing negative associations, and roughly 50% showing no significant association. Less well-studied candidate immune and inflammatory markers were also examined in relation to AD, such as IL-1β and IL-8, but the small body of existing studies showed inconsistent findings.[4]

While most studies analyzing CAIDE risk scores, ATN, and immune biomarkers have focused on older populations, their relationship with cognitive function in pre-midlife adults has rarely been investigated. This study aims to address several significant gaps in our understanding of AD risk in the US population by examining widely studied risk factors for AD and cognitive function prior to midlife. This is crucial because many have hypothesized that there is a long subclinical phase of AD but have rarely studied markers of AD in early adulthood. Specifically, we assessed the associations between CAIDE score, APOE ε4 status, two ATN biomarkers (total Tau and NfL), and several inflammatory molecules and interleukins (hsCRP, IL-1β, IL-6, IL-8, IL-10, TNF-α) with three standard measures of cognitive function in a US representative study of 24- to 44-year-old participants in the National Longitudinal Study of Adolescent to Adult Health (Add Health).[9] Our findings aim to shed light on the emergence of AD risk in early adulthood in the U.S. population over the forthcoming two to four decades.

Methods

Study Population: Data from Waves IV-V of the National Longitudinal Study of Adolescent to Adult Health (Add Health) were used for this study. Add Health is a nationally representative cohort study that has been tracking adolescent participants since 1994-1995 (Wave I) through four follow-up waves.[9]

Wave IV (n=15,701), conducted in 2008, when participants were aged 24-34 years, included in-home interviews, cognitive tests, physical exams, saliva collection, and dried blood spot collection from all eligible respondents. Wave V, conducted between 2016 and 2018 when participants were aged 34-44, was a mixed-mode survey combining in-person and web/mail surveys with a target of 12,300 survey participants, out of which 1,702 received in-home interviews. Cognitive tasks were administered in-person by field interviewers during the in-home interviews. All Wave V participants were invited to complete a separate "biovisit", including a physical exam and venous blood collection, resulting in visits arranged for 5,381 participants. Additional information on study design, response rates, sample collection, and testing procedures are available at Harris et al. 2019 and on the Add Health website (https://addhealth.cpc.unc.edu/). Participants who reported being currently pregnant were removed from analyses except those involving APOE status only.

Measures:

CAIDE Score. The CAIDE score is a weighted composite score based on established risk factors for dementia. There are two versions, both include age, education, biological sex, systolic blood pressure (SBP), body mass index (BMI), total cholesterol, and physical activity. Version 2 (v2)

adds APOE ε4 status. The weights are the coefficients as derived in the original study creating the CAIDE score.[3] We aimed to align as closely as possible with the variables used in the original study, while adapting to our specific sample and available data. A summary of the components and scoring is shown in Table 1.

APOE ε4. A total of N=11,550 participants had available genomic data. Imputation was performed using the Michigan Imputation Server on unphased data. Data were imputed to the 1000 Genomes Project phase 3 version 5.[10] Using the imputed rs7412 (R^2 score = 0.896) and rs429358 (R^2 score = 0.919) variants, we categorized participants as ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4. APOE status was defined by having at least one ε4 allele (i.e. those with APOE ε2/ε4, ε3/ε4, or ε4/ε4 phenotypes vs. ε2/ε2, ε3/ε3, or ε2/ε3).

Amyloid, Tau, and Neurodegeneration (ATN) Biomarkers. Among those who completed a separate biovisit in Wave V, N=4,940 venous blood samples were collected via phlebotomy. Using a digital enzyme-linked immunosorbent assay (ELISA), serum samples were assayed for NfL, and plasma samples were assayed for total Tau.

Immune Biomarkers. Among Wave IV respondents, 75.9% consented to contribute a dried blood spot (DBS) sample and to sample archival (N=11,917). DBS samples were assayed using a high-sensitivity ELISA for CRP (hsCRP) in DBS samples,[11] and subsequently archived. A subset of archived DBS samples with sufficient quantity (N=5,019) were later tested for additional inflammatory markers including interleukins (IL-6, IL-8, and IL-10) and TNF-α using a highly sensitive electrochemiluminescent immunoassay (ECLIA) modified for DBS samples.[12] In Wave

V, serum samples from the biovisit (N=4,940) were assayed for hsCRP immediately upon receipt at the testing laboratory using a hsCRP-specific particle enhanced immunonephelometric assay. Archived samples were later tested for inflammatory cytokines (IL-6, IL-10, IL-8, IL-1β, and TNF- α) using an ECLIA (https://addhealth.cpc.unc.edu/documentation/user-guides/). Units for all blood biomarkers are in pg/mL except for hsCRP (mg/L). Values were log-transformed then standardized.

Cognitive Function. Cognitive assessments were conducted in the entire sample in Wave IV (N=14,732) and those who received an in-home interview in Wave V (N=1,717). In each wave, three cognitive assessments included immediate word recall, delayed word recall, and digit span backwards. For word recall, participants were read a 15-word list and asked to recall as many of the 15 words as possible. Cognitive scores were standardized into a z-score for analysis, with a higher score indicating higher memory cognition.

Covariates. We identified covariates for inclusion based on Directed Acyclic Graphs (DAG) models.[13] Early life SES was operationalized using the social origins score, based on parental education, occupation and household income and receipt of public assistance.[14] Additional covariates include age at exam, educational attainment (at the same wave in which the biomarker is measured), sex assigned at birth, and an indicator for recent inflammatory conditions. A race/ethnicity variable was constructed from the Wave V survey and supplemented with Wave I data if missing. Participants self-selected one or more boxes from a list including “White”, “Black, African American”, “Hispanic”, “Asian”, “Pacific Islander”, “American Indian or

Alaska Native", and "Some other race or origin". Please see supplement 1 for more information on variables and conceptualization of race and ethnicity.

Analysis. The independent variable, dependent variable, and sample size of each analytic sample are shown in Table 2. Flow charts illustrating the selection of each sample are provided in the supplementary material. Survey-weighted descriptive statistics were compiled to characterize demographics and relevant study variables in each sample. To examine the cross-sectional associations between cardiovascular (e.g., CAIDE score), ATN, immune, and genetic risk with cognitive function, survey-weighted linear regressions were used to estimate β parameters for unadjusted and adjusted models with each independent variable predicting each individual cognitive score in the same wave. For the CAIDE score models, covariates included race/ethnicity categories, social origins score, and an indicator for inflammatory conditions. For the ATN and immune BB biomarker models, covariates included sex assigned at birth, race/ethnicity categories, educational attainment, age, and an indicator for recent inflammatory conditions. For the APOE status, covariates included age and sex assigned at birth.

Results

The weighted characteristics of each analytic are shown in Table 3, and a comparison with the overall Add Health sample is available in Table S2. In Wave IV, the analytic sample sizes ranged from N=4,507 for the immune risk factors to N=11,449 for the CAIDE score, with a median age of 28 years. About half of the participants in Wave IV were female (48-52% across analytic samples) and about a third had a college degree or higher (26-30%). Approximately 70% were White (71-72%), 13-15% were Black, and 9-10% were Hispanic. In Wave V, analytical samples

ranged from N=529 to N=1121 with a median age of 38 years. Approximately 45% were female (44-47%), and over a third had a college degree (33%-36%). Approximately 69% were White (68.3-69.3%), 20% were Black (17-20%), and 7-8% were Hispanic in Wave V.

CAIDE scores. In Wave IV, higher CAIDE scores (both versions) were statistically significantly associated with lower cognitive scores in all domains (Figure 1 and Table S3). At Wave V, higher CAIDE scores trended in the same negative direction of lower cognitive scores across measures, but the associations were not statistically significant (Figure 1 and Table S3). In supplementary analyses, we explored associations between CAIDE scores with cognitive measures across participants who had data on all variables and covariates in both Wave IV and Wave V (Supplementary Figure S3 and Table S4, N=412). Similar patterns were observed for both Waves IV and V, but some results became non-significant with reductions in sample size.

Apolipoprotein (APOE) ε4. There were no associations between having at least one ε4 allele and cognitive function in Wave IV nor Wave V (Figure 2 and Table S3). We also examined the same associations among participants who had data on all variables and covariates in both Wave IV and V (Supplementary Figure S3 and Table S4, N=1063). In this subsample, there were similarly no associations between APOE status and cognitive function.

ATN markers. There was a negative association between total Tau and immediate word recall at Wave V shown in Figure 3 and Supplementary Table S3 (β=-0.14, 95% CI: -0.24, -0.04), but not with delayed recall or the digit span backwards. Nfl was associated with lower backward digit span scores though it was not statistically significant (β=-0.08, 95% CI: -0.17, 0.01). There were no statistically significant associations with Nfl and the other cognitive measures.

Immune risk factors. Cross-sectional associations between each inflammatory biomarker and cognitive scores are shown in Figure 4. β estimates are also shown in Supplementary Table S3. In Wave IV, IL-6 and hsCRP were associated with lower backwards digit span scores, but the estimate for IL-6 was not statistically significant after adjusting for covariates (IL-6: β=-0.04 SDs, 95% CI:-0.08, 0.00, hsCRP: β= -0.04, 95% CI: -0.08, -0.002). None of the other biomarkers (TNF-α, IL-8, IL-10) were associated with lower cognitive scores in Wave IV (Table S3). In Wave V, IL-6 was associated with lower backward digit span (β=-0.10, 95% CI: -0.19, -0.01) and IL-8 was associated with lower cognitive scores in all domains (immediate recall: β=-0.18, 95% CI:-0.28, -0.09; delayed recall: β=-0.17, 95% CI:-0.29, -0.05; backward digit span: β=-0.19, 95% CI:-0.29, -0.09), even after adjustment for covariates. See Table S3 in the supplementary material for β estimates and 95% CIs of all the associations shown in the figures.

Discussion

Several key risk factors for AD were found to be associated with standard measures of cognition in 24- to 44-year-olds in the U.S., suggesting that these factors may be related to cognitive function decades before the onset of AD. The CAIDE score was consistently linked to all three cognitive function measures (immediate recall, delayed recall, and digit span backward). Notably, a key genetic risk factor, APOE ε4, was not associated with recall or digit span backward, suggesting that the effects of APOE ε4 may not become apparent until middle to older age. We also observed significant associations with ATN biomarkers. Specifically, total Tau was linked to lower immediate word recall but not backward digit span scores. Although higher levels of NfL showed a trend toward lower backward digit span scores, the association was not statistically significant. A limited number of immune markers were significantly associated with cognitive function at ages 24-34 years; however, some of these associations appeared to become

more robust in the following decade of life. For instance, IL-6 was not associated with backward digit span in Wave IV but showed a significant association with lower backward digit span in Wave V. Similarly, IL-8 was not associated with cognitive scores in Wave IV but was linked to cognitive function measures across all domains in Wave V. These findings suggest that cardiovascular, ATN, and immune markers may be associated with critical measures of cognitive function at much younger ages than previously recognized, with some associations becoming more prominent between the early midlife ages of 33 and 44.

We observed strong associations between the CAIDE score and all three measures of cognition. For example, among adults aged 24-34, each 1-point increase in the CAIDE score was associated with a 0.03 SD decrease in the average backward digit span score, adjusted for covariates (95% CI: -0.04, -0.02). Among adults aged 34-44, each 1-point increase in the CAIDE score was similarly associated with a 0.03 SD decrease in the average backward digit span score, adjusted for covariates (95% CI: -0.08, 0.02). The magnitudes of these associations were consistent across waves for each cognitive test, but they did not reach statistical significance in Wave V. It is possible that the reduced sample size in the sub-cohort that received follow-up cognitive assessments was too small to detect statistically significant associations. Prior research supports significant associations between the CAIDE score and cognitive function in older cohorts, although these relationships vary depending on the cognitive domain and study population. For instance, studies in a US cohort (mean age 60.1 years) and a Finnish cohort (mean age 52.4 years) found consistent associations between higher CAIDE scores at baseline and lower subsequent scores in all domains tested (including memory tasks).[15,16] In a New Zealand cohort, researchers identified an inverse association between the CAIDE score and midlife IQ and

subjective midlife cognitive problems at age 45.[2] However, a study in Northern Manhattan (mean age 64 years) found cross-sectional inverse associations between the CAIDE score and tests of executive function and processing speed, but no association with memory tests or decline in test scores over time.[17] Finally, a study in the UK (mean age 56 years) showed associations between the CAIDE score and declines in reasoning, vocabulary, and global cognitive scores, but not in memory scores.[18] Importantly, all these studies focused on midlife or older ages (i.e., the average ages in each sample were all above 45 years at baseline). To the best of our knowledge, no studies have examined the relationship between the CAIDE score and cognition in young adulthood and early midlife in the U.S. Our study contributes to this body of knowledge by suggesting that these significant associations are observable well before the age of 50.

In contrast to prior research on APOE ε4 and cognitive function in older populations, we did not observe significant associations between the APOE ε4 allele (heterozygous nor homozygous) and our measures of cognitive function. Our findings are consistent with previous studies suggesting that the impact of APOE ε4 is not evident in younger populations.[19,20] Taken together, these results support the hypothesis that tau-related pathology in conjunction with APOE ε4 may either accumulate gradually after age 50 or activate more rapidly in older age.[19,20] Future research tracking these associations in longitudinal studies, such as Add Health, may help uncover the critical temporal changes in cognition related to APOE ε4.

Of note, two key ATN biomarkers appear to be associated with different aspects of memory at ages 34-44. NfL was associated, though not statistically significantly, with lower digit span scores, a measure of working memory. In contrast, total Tau was significantly associated with

poorer immediate word recall, a measure of verbal episodic memory. Remarkably, these patterns are consistent with research on these markers in much older populations at risk of AD. For example, NfL, a marker of neuronal injury, has been shown to be particularly associated with working memory and processing speed.[20] A study involving older adults from the National Health and Nutrition Examination Survey (NHANES) revealed an inverse relationship between serum NfL levels and digit symbol substitution test (DSST) scores in older participants.[21] Our finding of an association between Tau levels and episodic memory is noteworthy because Tau has been shown to be cross-sectionally associated with worse episodic memory, particularly among older individuals, including those without significant cognitive impairment.[22] Together, these findings provide preliminary evidence that ATN biomarkers may influence episodic memory and working memory a decade before middle age. To our knowledge, these are the first findings to suggest that ATN biomarkers are associated with cognition in a relatively large sample of 34-44-year-olds. Future research examining these and other promising ATN biomarkers in younger individuals are warranted.

We observed that several immune markers were associated with cognitive measures at ages 24-34 years, with IL-6 and hsCRP being associated with backward digit span. In the next decade of life, IL-6 continued to be associated with backward digit span, while IL-1β and IL-8 appeared to be associated with word recall and backward digit span in Wave V, but not in Wave IV. In contrast, no associations were found with hsCRP in Wave V. Chronic systemic inflammation, often measured by elevated levels of inflammatory biomarkers like CRP and IL-6, has been linked to an increased risk of developing AD.[23] A recent review by Li et al. found that IL-6 was the most consistently associated biomarker with AD and IL-1B was also consistently positively

associated with AD.[4] However, these studies were mostly conducted in populations over the age of 50 years. Our findings suggest the potential emergence of IL-6 and IL-1β as important immune molecules related to cognition early in the life course, consistent with this review of later-life relationships. Our evidence for these immune and inflammatory relationships as early as the third and fourth decades of life, as observed in this study, is noteworthy and suggests that associations between these markers and cognition are apparent 10-20 years earlier than what prevailing theories suggest.[24]

This study has several limitations. Significant associations with CRP and TNF that we observed in Wave IV were not observed in Wave V and may be related to the smaller sample size in Wave V. The limited sample size and the availability of only two waves of data precluded us from examining trends over time and ATN biomarkers were only available in Wave V. The CAIDE score was originally derived from an older cohort in Finland and hasn't been extensively measured before middle age, but has been validated in older diverse cohorts in the US.[25] Wave IV samples were assayed using blood spots, while Wave V samples were assayed using serum or plasma. A few biomarkers, such as IL-8, showed lower agreement between blood spot and serum assays, as previously discussed.[12] This may have been due to the presence of red blood cells interfering with IL-8 assays. This discrepancy might explain why we observed an association between IL-8 and cognition in Wave V but not in Wave IV which used blood spot assays. Nonetheless, this study is groundbreaking because it is the first to examine key AD risk factors in a large diverse population-based sample of 24- to 44-year olds in the US.

In conclusion, our study highlights that key risk factors for AD including cardiovascular, ATN, and immune markers, are associated with cognitive function much earlier in life than previously recognized, with significant associations observed as early as 24-44 years of age. The CAIDE score, in particular, consistently predicted cognitive scores across multiple domains in young adults, while APOE ε4's impact may not emerge until later in life. ATN and immune and inflammatory biomarkers are already beginning to show associations with cognition pre-midlife. These findings suggest that the foundations for AD-related cognitive decline may be laid decades before clinical symptoms appear, underscoring the importance of early prevention and intervention strategies targeting these risk factors. Future research should continue to explore these associations longitudinally to better understand the timing of and mechanisms underlying cognitive function in relation to these markers.

Tables and Figures

Table 1. CAIDE Score Components

CAIDE Risk Factors	Version 1 Weighted Components	Version 2 Weighted Components
Age	Lowest tertile = 0 Middle tertile = 3 Highest tertile = 4	Lowest tertile = 0 Middle tertile = 3 Highest tertile = 5
Educational Attainment	College degree or higher = 0 Some college/technical training = 2 HS diploma/GED or less = 3	College degree or higher = 0 Some college/technical training = 3 HS diploma/GED or less = 4
Biological Sex	Female = 0 Male = 1	Female = 0 Male = 1
Systolic Blood Pressure	≤140 mm Hg = 0 >140 mm Hg = 2	≤140 mm Hg = 0 >140 mm Hg = 2
BMI	≤30 kg/m2 = 0 >30 kg/m2 = 2	≤30 kg/m2 = 0 >30 kg/m2 = 2
Total Cholesterol	Bottom 9 deciles = 0 Top decile = 2	Bottom 9 deciles = 0 Top decile = 1
Physical Activity	≥ activity 2x per week= 0 < activity 2x per week= 1	≥ activity 2x per week= 0 < activity 2x per week= 1
APOE e4 status	N/A	Non-ε4 carrier =0 ≤ 1 ε4 allele=2

Table 2. Analytic Samples

Wave	Sample	Independent Variable	Dependent Variable	Sample Size	Results shown
IV	CAIDE	CAIDE score	Cognitive Scores	N=11,449	Figure 1
V	CAIDE	CAIDE score	Cognitive Scores	N=529	Figure 1
IV	Genetic	APOE Status	Cognitive Scores	N=10,674	Figure 2
V	Genetic	APOE Status	Cognitive Scores	N=1,121	Figure 2
IV	Blood-Based Biomarker	Immune Risk Biomarkers	Cognitive Scores	N=4,507	Figure 4
V	Blood-Based Biomarker	ATN Biomarkers	Cognitive Scores	N=588	Figure 3
V	Blood-Based Biomarker	Immune Risk Biomarkers	Cognitive Scores	N=588	Figure 4

Table 3. Weighted Sample Characteristics, Add Health Wave IV-V

	Wave IV CAIDE Sample *n=11,449*		Wave V CAIDE Sample *n=529*		Wave IV Blood-Based Biomarker Sample *n=4,507*		Wave V Blood-Based Biomarker Sample *n=588*		Wave IV Genetic Sample *n=10,674*		Wave V Genetic Sample *n=1121*	
Age (years)	27.8	(26.3, 29.3)	38.4	(36.7, 39.7)	27.8	(26.3, 29.3)	38.2	(36.7, 39.7)	27.8	(26.3, 29.3)	37.9	(36.5, 39.4)
Sex												
Female	5984,	48.4%	277,	43.8%	2451,	52.1%	308,	43.6%	5704,	50.0%	581,	46.8%
Race												
American Indian or Alaska Native	116,	1.0%	--		42,	0.8%	--		79,	0.7%	--	
Asian	653,	2.9%	20,	2.4%	287,	3.5%	20,	2.1%	528,	2.5%	43,	2.5%
Black, African American	2262,	14.1%	104,	20.0%	815,	12.5%	117,	19.5%	2151,	14.9%	231,	17.1%
Hispanic	1530,	10.1%	59,	7.3%	624,	10.2%	74,	8.5%	1361,	9.3%	138,	9.6%
Pacific Islander	55,	0.3%	--		26,	0.3%	--		53,	0.3%	--	
Some other race or origin	35,	0.2%	--		13,	0.2%	--		32,	0.3%	--	
White	6798,	71.4%	338,	69.3%	2700,	72.5%	366,	68.7%	6470,	72.0%	686,	69.2%
Education												
College Degree or Higher	3665,	30.3%	208,	36.1%	1268,	26.4%	222,	33.4%	3354,	29.9%	375,	30.7%
Some College and/or Technical Training	5125,	43.7%	220,	44.1%	2106,	46.0%	248,	44.7%	4776,	43.4%	499,	44.8%
High School/GED or lower	2659,	26.0%	101,	19.8%	1133,	27.6%	118,	21.9%	2544,	26.6%	247,	24.4%
Recent Inflammatory Condition[a]	1788,	16.0%	82,	16.8%	747,	16.9%	95,	17.3%	1673,	15.9%	99,	9.6%
Social Origins Score[b]	0.1	(-0.7, 1.0)	0.3	(-0.6, 1.1)	0.1	(-0.7, 0.9)	0.2	(-0.7, 1.1)	0.2	(-0.7, 1.0)	0.1	(-0.8, 1.0)
CAIDE score v1[c]	5.2	(3.2, 7.2)	6.1	(3.9, 8.0)	5.4	(3.3, 7.3)	6.2	(3.9, 8.1)	5.3	(2.5, 4.8)	6.1	(3.8, 7.9)
CAIDE score v2[c] (with APOE status)	6.7	(4.3, 9.1)	7.7	(5.3, 9.9)	7.0	(4.5, 9.3)	7.7	(5.3, 10.0)	6.8	(4.3, 9.1)	7.6	(5.1, 9.8)
missing	*2764*		*9*		*795*		*41*		*1128*		*568*	
Blood-based Biomarkers (log-transformed)												
hsCRP (mg/L)	0.7	(-0.3, 1.6)	0.6	(-0.3, 1.5)	0.8	(-0.2, 1.7)	0.7	(-0.2, 1.6)	0.8	(-0.2, 1.7)	0.7	(-0.2, 1.7)
TNF-α (pg/mL)	1.1	(0.9, 1.3)	0.9	(0.7, 1.5)	1.1	(0.9, 1.3)	0.9	(0.7, 1.1)	1.1	(0.9, 1.3)	0.9	(0.7, 1.1)

IL-6 (pg/mL)	-0.2	(-0.6, 0.3)	-0.3	(-0.8, 0.1)	-0.2	(-0.6, 0.3)	-0.3	(-0.7, 0.2)	-0.2	(-0.6, 0.3	-0.3	(-0.7, 0.2)
IL-10 (pg/mL)	-0.9	(-1.4, -0.4)	-1.5	(-1.8, -1.1)	-0.9	(-1.4, -0.4)	-1.5	(-1.8, -1.1)	-0.9	(-1.4, -0.4)	-1.5	(-1.8, -1.1)
IL-8 (pg/mL)	4.3	(4.0, 4.6)	2.6	(2.3, 3.0)	4.3	(4.0, 4.6)	2.6	(2.3, 3.0)	4.3	(4.0, 4.6)	2.6	(2.3, 3.0)
IL-1B (pg/mL)	NA		-3.7	(-5.0, -2.9)	NA		-3.7	(-5.0, -2.9)	NA		-3.7	(-5.0, -2.9)
NfL (pg/mL)	NA		1.9	(1.6, 2.2)	NA		1.9	(1.6, 2.2)	NA		1.9	(1.6, 2.2)
total Tau (pg/mL)	NA		0.8	(0.5, 0.8)	NA		0.8	(0.4, 1.1)	NA		0.8	(0.4, 1.1)
APOE ε4 status												
ε4 carrier (ε2/ε4, ε3/ε4, or ε4/ε4)	2368,	27.3%	154,	29.1%	1043,	27.0%	169,	27.6%	2943,	27.4%	315,	27.6%
missing	*2764*		*9*		*659*		*9*		*0*		*0*	
Cognitive Function Tests												
Immediate Word Recall	6.0	(4.8, 7.4)	5.8	(4.5, 7.1)	6.1	(4.8, 7.5)	5.6	(4.4, 7.0)	6.0	(4.8, 7.4)	5.6	(4.3, 6.9)
Delayed Word Recall	4.6	(3.3, 5.9)	4.3	(2.9, 5.6)	4.7	(3.4, 6.0)	4.1	(2.7, 5.4)	4.6	(3.3, 6.0)	4.1	(2.8, 5.4)
Backwards Digit Span	3.5	(2.5, 4.8)	3.6	(2.4, 5.1)	3.6	(2.5, 4.9)	3.5	(2.4, 5.0)	3.5	(2.5, 4.8)	3.5	(2.4, 4.9)

Data are shown as N, survey-weighted % for categorical variables and weighted median, (IQR) for continuous variables.

[a]Indicator of any of the following conditions: gum disease, active infection, injury, acute illness, and/or surgery in the past 4 weeks, and/or fever in the past 2 weeks. Reported use of cox-2 inhibitors, corticotrophines, glucocorticords, anti-rheumatics, anti-psoriatics, immunosuppressive agents or monoclonal antibodies in the past 4 weeks included in Wave V

[b]Factor score based on Wave I parental reports of education, occupation, household income, and household receipt of public assistance (standardized to a z-score for analysis)[12].

[c]Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score version 1 is a weighted sum of education, sex, age, total cholesterol, systolic blood pressure, body mass index, and physical activity. Version 2 includes the same variables and adds APOE ε4 carrier status.

Figure 1. Association between CAIDE Score and Cognitive Test Scores, Add Health Wave IV and Wave V



Each panel shows the β estimates and 95% CIs for survey-weighted linear regressions where CAIDE scores are the independent variable and cognitive function tests scores are the dependent variable.
Models are adjusted for race/ethnicity, social origin score, and an indicator for recent inflammatory conditions.
Wave IV: N=11,449 for the CAIDE v1 score, N=8,685 for the CAIDE v2 score (with APOE e4 carrier status).
Wave V: N=529 for CAIDE score v1, N=520 for the CAIDE score v2.

Figure 2. Association Between APOE Status and Cognitive Function, Add Health Wave IV and Wave V



Each panel shows the β estimates and 95% CIs for survey-weighted linear regressions where APOE e4 carrier status (carrier vs. non-carrier) is the independent variable and cognitive function tests scores are the dependent variable.
Models adjusted sex assigned at birth and age.
Wave IV N=10,674
Wave V N=1,121

Figure 3. Association Between Amyloid, Tau, and Neurodegeneration (ATN) Biomarkers and Cognitive Function, Add Health Wave V, N=588



Each panel shows the β estimate and 95% CI for survey-weighted linear regressions where Wave V blood-based ATN biomarker concentrations are the independent variable and Wave V cognitive function tests scores are the dependent variable.
Models adjusted for race/ethnicity, education, sex assigned at birth, age, and an indicator for inflammatory conditions.
NfL N=588, total Tau N=584

Figure 4. Association between Immune Risk Biomarkers and Cognitive Test Scores, Add Health Wave IV and Wave V



Each panel shows the β estimates and 95% CIs for cross-sectional survey-weighted linear regressions where inflammatory biomarker concentrations are the independent variable and cognitive function tests scores are the dependent variable. Wave IV cross-sectional associations are on the left and Wave V cross-sectional associations are on the right.
Models adjusted for race/ethnicity, educational attainment, sex assigned at birth, age, and an indicator for inflammatory conditions
Wave IV (dried blood spots): N=4485 for hsCRP, N=4507 for all other biomarkers
Wave V (serum): N=567 for hsCRP, N=588 for all other biomarkers.

References

1. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet* 2020; 396: 413–446.

2. Reuben A, Moffitt TE, Abraham WC, et al. Improving risk indexes for Alzheimer's disease and related dementias for use in midlife. *Brain Communications* 2022; 4: fcac223.

3. Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *The Lancet Neurology* 2006; 5: 735–741.

4. Li C, Stebbins RC, Noppert GA, et al. Peripheral immune function and Alzheimer's disease: a living systematic review and critical appraisal. *Molecular Psychiatry*. Epub ahead of print 15 December 2023. DOI: 10.1038/s41380-023-02355-x.

5. Raulin A-C, Doss SV, Trottier ZA, et al. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. *Molecular Neurodegeneration* 2022; 17: 72.

6. Li R-X, Ma Y-H, Tan L, et al. Prospective biomarkers of Alzheimer's disease: A systematic review and meta-analysis. *Ageing Research Reviews* 2022; 81: 101699.

7. Lu Y, Pike JR, Chen J, et al. Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia. *JAMA*. Epub ahead of print 28 July 2024. DOI: 10.1001/jama.2024.6619.

8. Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. *JAMA neurology* 2019; 76: 598–606.

9. Harris KM, Halpern CT, Whitsel EA, et al. Cohort Profile: The National Longitudinal Study of Adolescent to Adult Health (Add Health). *International Journal of Epidemiology* 2019; 48: 1415–1415k.

10. Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and methods. *Nature Genetics* 2016; 48: 1284–1287.

11. McDade TW, Burhop J, Dohnal J. High-Sensitivity Enzyme Immunoassay for C-Reactive Protein in Dried Blood Spots. *Clinical Chemistry* 2004; 50: 652–654.

12. McDade TW, Miller A, Tran TT, et al. A highly sensitive multiplex immunoassay for inflammatory cytokines in dried blood spots. *American Journal of Human Biology* 2021; 33: e23558.

13. Greenland S, Pearl J, Robins JM. Causal Diagrams for Epidemiologic Research. *Epidemiology* 1999; 10: 37–48.

14. Belsky DW, Domingue BW, Wedow R, et al. Genetic analysis of social-class mobility in five longitudinal studies. *Proceedings of the National Academy of Sciences* 2018; 115: E7275–E7284.

15. Stephen R, Liu Y, Ngandu T, et al. Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition. *Journal of Alzheimer's Disease* 2017; 59: 695–705.

16. Schaich CL, Yeboah J, Espeland MA, et al. Association of Vascular Risk Scores and Cognitive Performance in a Diverse Cohort: The Multi-Ethnic Study of Atherosclerosis. *The Journals of Gerontology: Series A* 2022; 77: 1208–1215.

17. Rundek T, Gardener H, Dias Saporta AS, et al. Global Vascular Risk Score and CAIDE Dementia Risk Score Predict Cognitive Function in the Northern Manhattan Study. *Journal of Alzheimer's Disease* 2020; 73: 1221–1231.

18. Kaffashian S, Dugravot A, Elbaz A, et al. Predicting cognitive decline. *Neurology* 2013; 80: 1300–1306.

19. Deary IJ, Whiteman MC, Pattie A, et al. Cognitive change and the APOE ε4 allele. *Nature* 2002; 418: 932–932.

20. Rawle MJ, Davis D, Bendayan R, et al. Apolipoprotein-E (Apoe) ε4 and cognitive decline over the adult life course. *Translational Psychiatry* 2018; 8: 18.

21. Gao Y, Su D, Xue Z, et al. Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study. *Neurology and Therapy* 2023; 12: 2147–2160.

22. Pelgrim TAD, Beran M, Twait EL, et al. Cross-sectional associations of tau protein biomarkers with semantic and episodic memory in older adults without dementia: A systematic review and meta-analysis. *Ageing Research Reviews* 2021; 71: 101449.

23. Walker KA, Ficek BN, Westbrook R. Understanding the Role of Systemic Inflammation in Alzheimer's Disease. *ACS Chem Neurosci* 2019; 10: 3340–3342.

24. National Institute on Aging. *Alzheimer's Disease: Unraveling the Mystery*. NIH Publication Number 08-3782, Health and Human Services Department, Office of Public Health and Science, 2008.

25. Exalto LG, Quesenberry CP, Barnes D, et al. Midlife risk score for the prediction of dementia four decades later. *Alzheimer's & Dementia* 2014; 10: 562–570.